PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).
Not Applicable
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Registration Number
- NCT05602259
- Lead Sponsor
- Centre Hospitalier Universitaire de Liege
- Brief Summary
This prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
-
o All stages of NSCLC
- Stage III-IV NSCLC eligible for ICI treatment
- 18 years or older; non pregnant women
- in stage III-IV: no previous ICI and before ICI (mono- or combination therapy) initiation
- Signed informed consent
- Clinical, biological and radiological evaluation at the CHU de Liège for at least 6 months following treatment initiation
Exclusion Criteria
- Probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors)
- Inclusion in a clinical study contraindicating the enrolment in the PROTEON study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Detection of eosinophils in untreated non-small cell lung cancer patients Baseline (pre-treatment) Concentration of eosinophils will be used in various bodily materials as described above.
- Secondary Outcome Measures
Name Time Method Prognostic and predictive value of eosinophils in non-small cell lung cancer patients Baseline (pre-treatment) and, if immunotherapy, after 3 months of treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link eosinophilia to prognosis in non-small cell lung cancer?
How does eosinophil detection in biological materials compare to standard-of-care biomarkers in NSCLC?
What are the predictive biomarkers for eosinophil-associated outcomes in untreated NSCLC patients?
What adverse events are associated with eosinophil-targeted therapies in lung cancer treatment?
Are there combination approaches involving eosinophil modulation and existing NSCLC treatments?
Trial Locations
- Locations (1)
CHU de Liège
🇧🇪Liège, Belgium
CHU de Liège🇧🇪Liège, BelgiumAnne Sibille, MDContact+3243237400anne.sibille@chuliege.beAurore Cue AlvarezContact+3243235539aurore.cuealvarez@chuliege.be